The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
- 1 June 1994
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 46 (5), 405-410
- https://doi.org/10.1007/bf00191901
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with HypercholesterolemiaNew England Journal of Medicine, 1993
- Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemiaThe American Journal of Cardiology, 1992
- Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in manThe Lancet, 1992
- Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dl (5.18 to 6.21 mmol/liter)The American Journal of Cardiology, 1991
- Dietary reduction of serum cholesterol concentration: time to think again.BMJ, 1991
- Can lifestyle changes reverse coronary heart disease?The Lancet, 1990
- Guar GumDrugs, 1990
- Lipid related consequences of intestinal malabsorption.Gut, 1989
- Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
- Effects of Neomycin Alone and in Combination with Cholestyramine on Serum Cholesterol and Fecal Steroids in Hypercholesterolemic SubjectsJournal of Clinical Investigation, 1979